| Pacritinib |
NCT02765724 |
Completed |
Phase 1 |
Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects |
Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02765724 |
| Pacritinib |
NCT02803762 |
Completed |
Phase 1 |
Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib |
Healthy |
https://ClinicalTrials.gov/show/NCT02803762 |
| Pacritinib |
NCT02532010 |
Terminated |
Phase 2 |
Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML |
Acute Myeloid Leukemia (AML) |
https://ClinicalTrials.gov/show/NCT02532010 |
| Pacritinib |
NCT02807051 |
Completed |
Phase 1 |
To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects |
Drug Interaction Study |
https://ClinicalTrials.gov/show/NCT02807051 |
| Pacritinib |
NCT02807116 |
Completed |
Phase 1 |
Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects |
Healthy Subjects |
https://ClinicalTrials.gov/show/NCT02807116 |
| Pacritinib |
NCT02055781 |
Terminated |
Phase 3 |
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia |
Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02055781 |
| Pacritinib |
NCT03645824 |
Recruiting |
Phase 2 |
Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) |
Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03645824 |
| Pacritinib |
NCT03165734 |
Recruiting |
Phase 2|Phase 3 |
A Phase 2/3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis |
Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT03165734 |
| Pacritinib |
NCT01773187 |
Terminated |
Phase 3 |
Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis |
Primary Myelofibrosis|Post-polycythemia Vera Myelofibrosis|Post-essential Thrombocythemia Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01773187 |
| Pacritinib |
NCT03601819 |
Recruiting |
Phase 1 |
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders |
Lymphoma, T-Cell, Cutaneous|Lymphoma, T-Cell, Peripheral|Chronic Lymphocytic Leukemia|Lymphoproliferative Disorders|Waldenstrom Macroglobulinemia|Lymphoplasmacytic Lymphoma|Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03601819 |
| Pacritinib |
NCT02677948 |
Withdrawn |
Phase 1|Phase 2 |
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
Chronic Lymphocytic Leukemia|Lymphoma, Small Lymphocytic |
https://ClinicalTrials.gov/show/NCT02677948 |
| Pacritinib |
NCT02277093 |
Terminated |
Phase 2 |
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer |
Colorectal Cancer |
https://ClinicalTrials.gov/show/NCT02277093 |
| Pacritinib |
NCT02410551 |
Terminated |
Phase 2 |
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN) |
Myeloproliferative Diseases |
https://ClinicalTrials.gov/show/NCT02410551 |
| Pacritinib |
NCT02564536 |
Withdrawn |
Phase 1 |
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) |
Chronic Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia|Atypical Chronic Myeloid Leukemia|Myeloproliferative Neoplasm|Myelodysplastic Syndromes|Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02564536 |
| Pacritinib |
NCT02469415 |
Terminated |
Phase 2 |
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) |
Leukemia |
https://ClinicalTrials.gov/show/NCT02469415 |
| Pacritinib |
NCT02807077 |
Completed |
Phase 1 |
PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects |
Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02807077 |
| Pacritinib |
NCT02808455 |
Completed |
Phase 1 |
Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects |
Healthy Subjects |
https://ClinicalTrials.gov/show/NCT02808455 |
| Pacritinib |
NCT02891603 |
Recruiting |
Phase 1|Phase 2 |
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression |
Graft Vs Host Disease|GVHD |
https://ClinicalTrials.gov/show/NCT02891603 |
| Pacritinib |
NCT02584777 |
Withdrawn |
Phase 2 |
A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis |
Primary Myelofibrosis |
https://ClinicalTrials.gov/show/NCT02584777 |
| Pacritinib |
NCT02323607 |
Completed |
Phase 1 |
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations |
Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT02323607 |
| Pacritinib |
NCT02342353 |
Terminated |
Phase 1 |
Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) |
Non-Small Cell Lung Cancer|Nonsmall Cell Lung Cancer|Carcinoma, Non-Small-Cell Lung |
https://ClinicalTrials.gov/show/NCT02342353 |
| Pacritinib |
NCT02823171 |
Completed |
Phase 1 |
To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects |
Healthy |
https://ClinicalTrials.gov/show/NCT02823171 |
| Pacritinib |
NCT02807207 |
Completed |
Phase 1 |
To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects |
Healthy Subjects |
https://ClinicalTrials.gov/show/NCT02807207 |
